| Name | Title | Contact Details |
|---|
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is an oncology-focused pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm`s SINE compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm`s lead compound, XPOVIO™ (selinexor), received accelerated approval from the FDA in July 2019 in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. A Marketing Authorization Application for selinexor is also currently under review by the European Medicines Agency. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development.
Cardiocore Lab, Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
Sigmapharm Laboratories LLC
Telehealth Available: Trusted Addiction Medicine serving the greater Phoenix, AZ area. Visit our website to book an appointment online: 2nd Chance Treatment Center
Andau Medical is a Canadian Medical Device and Dental Device company focused on providing the market with quality technologies that improve patient outcomes and enhance the clinical experience in delivering exceptional patient care.